

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.
三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2197)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON JUNE 19, 2025
AND
RETIREMENT OF NON-EXECUTIVE DIRECTOR**

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 19, 2025

The board (the “**Board**”) of directors (the “**Directors**”) of Clover Biopharmaceuticals, Ltd. (the “**Company**”) is pleased to announce the poll results of the annual general meeting of the Company (the “**Annual General Meeting**”) held at B5-19, Building 1, High-tech Incubation Park, No. 1480, Tianfu Avenue (North), Chengdu High-Tech Zone, China (Sichuan) Pilot Free Trade Zone on Thursday, June 19, 2025 at 10:00 a.m.

References are made to the Company’s circular (the “**Circular**”) in connection with the Annual General Meeting and notice of the Annual General Meeting (the “**Notice**”) dated May 21, 2025. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The poll results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended December 31, 2024.	428,850,356 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
2.	To re-elect the following persons:		
	(a) Dr. Donna Marie AMBROSINO, non-executive director	428,850,356 (100.000000%)	0 (0.000000%)
	(b) Mr. Thomas LEGGETT, independent non-executive director	428,850,356 (100.000000%)	0 (0.000000%)
3.	To authorise the board of directors of the Company to fix the remuneration of the directors.	428,850,356 (100.000000%)	0 (0.000000%)
4.	To appoint CL Partners CPA Limited as the auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the board of directors of the Company to fix its remuneration.	428,850,356 (100.000000%)	0 (0.000000%)
5.	(A) To give a general mandate to the directors of the Company to allot, issue and deal with additional shares and/or sell or transfer treasury shares (if any) not exceeding 20% of the issued share capital of the Company (excluding treasury shares, if any) as at the date of this resolution.	428,850,356 (100.000000%)	0 (0.000000%)
	(B) To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the issued share capital of the Company (excluding treasury shares, if any) as at the date of this resolution.	428,850,356 (100.000000%)	0 (0.000000%)
	(C) To extend the authority given to the directors of the Company pursuant to ordinary resolution no. 5(A) to issue shares and/or sell or transfer treasury shares (if any) by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 5(B).	428,850,356 (100.000000%)	0 (0.000000%)

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

As more than 50% the votes were cast in favour of each of the resolutions numbered 1 to 5 above, all such resolutions were duly passed as ordinary resolutions at the Annual General Meeting.

The total number of issued Shares as at the date of the Annual General Meeting was 1,297,062,429 Shares. As set out in the Circular, the Trustee will abstain from voting on all resolutions to be proposed at the Annual General Meeting. Therefore, the Trustee, holding a total number of 57,773,895 Shares as at the date of the Annual General Meeting, has abstained from voting on all resolutions proposed at the Annual General Meeting.

Save as disclosed above, there were (i) no Shareholders being required under the Listing Rules to abstain from voting in respect of the resolutions at the Annual General Meeting and no Shareholders stating his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Annual General Meeting, (ii) no restrictions on any Shareholders casting votes on any of the proposed resolutions at the Annual General Meeting, and (iii) no Shares entitling the holders to attend and abstain from voting in favour of any resolution at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules. Accordingly, the total number of Shares of the Company entitling the holders to attend and vote on the resolutions numbered 1 to 5 above was 1,239,288,534 Shares as at the date of the Annual General Meeting.

Except for Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO, Dr. Ralf Leo CLEMENS, Dr. Xiaobin WU, Mr. Xiang LIAO and Mr. Thomas LEGGETT who did not attend the Annual General Meeting due to business arrangements, all other Directors of the Company, namely Dr. Peng LIANG, Mr. Joshua G LIANG and Mr. Jeffrey FARROW attended the Annual General Meeting, either in person or by means of electronic facilities.

Computershare Hong Kong Investor Services Limited, the branch share registrar in Hong Kong of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

RETIREMENT OF NON-EXECUTIVE DIRECTOR

As disclosed in the Circular, Dr. Ralf Leo CLEMENS (“**Dr. Clemens**”) did not stand for re-election at the Annual General Meeting due to his need to allocate more time to family and personal affairs. Accordingly, Dr. Clemens has retired as a non-executive Director at the conclusion of the Annual General Meeting. Dr. Clemens continues to serve as the chairman of the vaccine scientific advisory board of the Company.

Dr. Clemens has confirmed that (i) he has no disagreement with the Board; and (ii) there are no matters with respect to his retirement that need to be brought to the attention of the Stock Exchange or the Shareholders.

The Board would like to extend its gratitude to Dr. Clemens for his valuable contributions to the Company during his tenure of service.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, June 19, 2025

As of the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive Directors; Dr. Xiaodong WANG and Dr. Donna Marie AMBROSINO as non-executive Directors; and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive Directors.